Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session
Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01…Read More
You might also be interested in reading All eyes are on Nvidia as key earnings could impact hundreds of ETFs.